Barr Pharmaceuticals (BRL) Receives Approval From FDA For Estrostep(R)
More News related to BRL
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw Announces Appointment of Director
- Bearclaw's President Dies Suddenly
More News related to FDA
- BSD Medical (BSDM) Initiates Phase 3 Clinical Study of BSD-2000 Hyperthermia System
- Novartis (NVS) Gains Rights to Develop and Distribute Debio 025; Currently in Phase IIb
- Dynavax Tech (DVAX) Initiates HEPLISAV Phase 3
- Cerus Corp. (CERS) Enters Into Agreement with EFS for INTERCEPT Blood System Development
- Sequenom (SQNM) Gets Rights to Develop and Commercialize to Predict Genetic Predisposition for Macular AMD
Barr Pharmaceuticals (NYSE: BRL) today announced it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA) to manufacture and market a generic version of Warner Chilcott Company, Inc.'s Estrostep(R) Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets) oral contraceptive product. The Company will launch its product immediately under the tradename TriLegest(TM) Fe.
Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide. Barr operations are based primarily in North America and Europe, with key markets being the United States, Croatia, Germany, Poland and Russia.
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
